Orexin neurons are localized exclusively in certain hypothalamic areas (lateral hypothalamic area, perifornical area, and posterior hypothalamus) ( Figure 1 ). [1] [2] [3] These orexin neurons make the neurotransmitters orexin A and orexin B, which are released from their neuronal projections all over the brain, but especially in the monoamine neurotransmitter centers in the brainstem ( Figure 1 ). [1] [2] [3] The postsynaptic actions of the orexins are mediated by 2 receptors, called orexin 1 and orexin 2 ( Figure 2 ). [1] [2] [3] The neurotransmitter orexin A interacts with both orexin 1 and 2 receptors, but orexin B interacts only with orexin 2 receptors ( Figure 2 Figure 3 ).
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Lack of orexins is associated with narcolepsy. [1] [2] [3] Reversible pharmacologic blockade of orexin receptors is now proven to be a novel hypnotic mechanism ( Figure 4 ). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Other potential clinical applications, based on preclinical studies, could eventually include use for weight loss or drug abuse. 1, 4, 6, 7, 12 Dual orexin receptor antagonists (DORAs) that block both orexin 1 and 2 receptors, and single orexin receptor antagonists (SORA-1s and SORA-2s) that selectively block either orexin 1 receptors or orexin 2 receptors, have also been developed ( Figure 4 ) and are being extensively tested at this time.
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The novel DORA suvorexant is now an approved hypnotic that improves both the initiation and maintenance of sleep in human subjects, without the side effects expected of a benzodiazepine or Z drug hypnotic, namely, dependence, withdrawal, rebound, unsteady gait, falls, confusion, amnesia, or respiratory depression. [1] [2] [3] [12] [13] [14] [15] [16] Figure 2. Hypocretin/orexin neurotransmission is mediated by 2 types of postsynaptic G-protein-coupled receptors, orexin 1 (Ox1R) and orexin 2 (Ox2R). The neurotransmitter orexin A is capable of interacting with both Ox1R and Ox2R, whereas the neurotransmitter orexin B binds selectively to Ox2R. The binding of orexin A to Ox1R leads to increased intracellular calcium as well as activation of the sodium/calcium exchanger. The binding or orexin A or B to Ox2R leads to increased expression of N-methyl-D-aspartate (NMDA) glutamate receptors as well as inactivation of G-protein-regulated inwardly rectifying potassium (GIRK) channels. Ox1R's are highly expressed in the noradrenergic locus coeruleus, whereas Ox2R's are highly expressed in the histaminergic tuberomammillary nucleus (TMN). Figure 3 . During periods of wakefulness and partly under the control of the circadian drive from light/dark cycles, hypocretin/orexin neurons are active and fire with tonic frequency to maintain arousal. When presented with a stimulus (either external, such as an escapable stressor, or internal, such as elevated CO 2 levels), hypocretin/orexin neurons exhibit a more rapid phasic burst firing pattern. This excitement of hypocretin/orexin neurons leads to increased neurotransmission and the activation of other brain areas and peripheral responses, which in turn leads to the execution of appropriate behavioral responses. These behavioral responses lead to the attainment of reward or the avoidance of potential danger. In this way, the hypcretin/orexin system not only mediates wakefulness, but also allows for the facilitation of goal-directed, motivated behaviors, including increased food intake in response to hunger. 
